Sleep Medicine
Volume 10 , Pages S22-S25 , September 2009

Health economics of insomnia therapy: Implications for policy

  • Marc Botteman

      Affiliations

    • Corresponding Author InformationTel.: +1 301 941 1942; fax: +1 301 656 0183.

References 

  1. National Institutes of Health. NIH state-of-the-science conference statement on manifestations and management of chronic insomnia in adults. NIH Consens Sci Statements 13–15 June 2005; 22(2): 1–30.
  2. National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia; 2004 [updated 2004, cited]. Available from: http://www.nice.org.uk/TA077.
  3. Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care. 2006;12(Suppl. 8):S246–S252
  4. Bureau USC. Global population profile 2002. Appendix A; 2002 [updated 2002, cited]. Available from: http://www.census.gov/ipc/prod/wp02/appA.html.
  5. Datamonitor. Commercial insight: insomnia – strong brand identity critical to differentiation in an increasingly crowded market (DMHC2306); 27 June 2007.
  6. Congressional Budget Office. Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role; 2007 [updated 2007 December, cited 03 June 2009]. Available from: http://www.cbo.gov/ftpdocs/88xx/doc8891/12-18-ComparativeEffectiveness.pdf.
  7. Orszag PR, Ellis P. The challenge of rising health care costs–a view from the Congressional Budget Office. N Engl J Med. 2007;357(18):1793–1795
  8. Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004;8(8):iii–ivp. 1–68
  9. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793–799
  10. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, et al. Nightly treatment of primary insomnia with eszopiclone for 6months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959–968
  11. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5mg, administered 3–7 nights per week for 24weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79–90
  12. Matsuo N, Morita T. Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: a retrospective multicenter audit study. J Palliat Med. 2007;10(5):1054–1062
  13. Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallieres A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161(2):332–342
  14. Sweet B. The wellpoint outcomes based formulary; 2006 [updated 2006, cited]. Available from: http://www.fmcpnet.org/data/resource/Brian%20SweetSeattle2006.pdf.
  15. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood), Suppl. Web Exclusives: W4-284-96; January–June 2004.
  16. Neumann PJ, Lin PJ, Greenberg D, Berger M, Teutsch S, Mansley E, et al. Do drug formulary policies reflect evidence of value?. Am J Manag Care. 2006;12(1):30–36
  17. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–1258
  18. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51(3):229–235
  19. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making. 2001;21(2):105–112
  20. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev. 2004;8(1):63–72
  21. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs. 2007;21(4):319–334
  22. Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8(24):iii–xp. 1-125
  23. Jhaveri M, Seal B, Pollack M, Wertz D. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin. 2007;23(6):1431–1443
  24. Snedecor SJ, Botteman MF, Schaefer K, Barry N, Pickard A. Cost-effectiveness of eszopiclone for the treatment of adults with primary insomnia. Sleep. 2008;31(Suppl.):A246

PII: S1389-9457(09)00250-0

doi: 10.1016/j.sleep.2009.07.001

Sleep Medicine
Volume 10 , Pages S22-S25 , September 2009

Article Tools

* Image Usage & Resolution